期刊文献+

肺癌患者经外周静脉置入中心静脉导管置入部位医用粘胶相关性皮肤损伤的多因素分析 被引量:22

Multivariate analysis of medical adhesive-related skin injury in peripherally inserted central catheter implanted patients with lung cancer
原文传递
导出
摘要 目的分析肺癌患者经外周静脉置人中心静脉导管(PICC)置入部位医用粘胶相关性皮肤损伤(MARSI)发病情况及相关因素,为优化临床护理方案提供依据。方法2017年1至9月在上海交通大学附属胸科医院经外周静脉置入的中心静脉导管(PICC)门诊开展横断面观察性研究,在PICC护理过程中采集皮肤图片及电子病历进行分类。统计MARSI发病率,分析其相关因素。结果MARSI的总发生率为31.5%(63/200),其中机械性皮肤损伤32例,占总发病类型的50.8%。年龄、糖尿病及过敏史对MARSI的发生有显著影响(P〈0.05)。结论肺癌患者PICC置入部位MARSI相关因素数据分析,为肺癌PICC置管患者MARSI护理方案的研究与制定提供依据。 Objective To analyze prevalence and determinants of medical adhesive-related skin injury (MARSI) in peripherally inserted central catheter implanted patients with lung cancer, to create evidence for im- proved clinical care. Methods A cross-sectional observational study design was adopted. Skin pictures and elec- tronic medical records of 200 lung cancer patients who visited Shanghai Chest Hospital for PICC between June 2017 and September 2017 were analyzed to calculate prevalence of MARSI and identify related factors. Results The prevalence of MARSI was 31.5% (63/200) , and mechanical trauma accounted for 50. 8% of all cases (32/ 63). Age, diabetes and anaphylaxis were significantly related to MARSI. Conclusion Analysis of MARSI in PICC implanted patients with lung cancer provided evidence for improved clinical care of such patients.
作者 王铮 万光明 潘璐意 王懿 Wang Zheng, Wan Guangming, Pan Luyi, Wang Yi.(Department of Outpatient Clinic, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai 200030, Chin)
出处 《中华临床营养杂志》 CAS CSCD 2018年第3期191-194,共4页 Chinese Journal of Clinical Nutrition
关键词 经外周静脉置入中心静脉导管 医用粘胶 皮肤损伤 Peripherally inserted central catheter Medical adhesive-related Skin injury
  • 相关文献

参考文献4

二级参考文献56

  • 1唐春花.38例糖尿病患者并发皮肤完整性受损的创面护理[J].当代护士(中旬刊),2003,10(6):22-24. 被引量:3
  • 2王晓辉,吴斌,朱珺.小分子靶向药物治疗非小细胞肺癌的不良事件研究进展[J].中国药房,2011,22(14):1329-1331. 被引量:5
  • 3王祥麒,王璇.脾肾双补法治疗伊立替康所致延迟性腹泻25例临床疗效观察[J].中医药学报,2011,39(4):118-119. 被引量:9
  • 4何华英,杜峻,王素芳,黄百发,蔡秀容,王捷.压疮危险因素预测及预防护理研究进展[J].护士进修杂志,2005,20(9):803-805. 被引量:253
  • 5Lynch TJ Jr,Kim E,Eady B,et al.Epidermal growth factor receptor inhibitor-associated cutaneous toxicities:An evolving paradigm in clinical management[J].Oncologist,2007,12(5):610.
  • 6Ocvirk J,Cencelj S.Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer[J].J Eur Acad Dermatol Venereol,2010,24(4):453-459.
  • 7Jatoi A,Nguyen PL.Do patients die from rashes fromepidermal growth factor receptor inhibitors?A systematic review to help counsel patients about holding therapy[J].Oneologist,2008,13(11):1201-1204.
  • 8Shah N T,Kris M G,Pao W,et al.Practical management of patients with non small cell lung cancer treated with gefitinib[J].J Clin Oncol,2005,23:165-174.
  • 9王洁,张力,周彩存,等.表皮生长因子受体抑制剂(EGFRIs)相关皮肤不良反应中国临床治疗指导原则(第三稿)—第二届中国肿瘤内科大会论文集[C].2012.
  • 10Segaert S,Van Cutsem E.Clinical signs,pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors[J].Ann Oncol,2005,16:1425-1433.

共引文献92

同被引文献195

引证文献22

二级引证文献99

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部